93 related articles for article (PubMed ID: 21711071)
21. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
22. A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes.
Orr RK; Col NF; Kuntz KM
Surgery; 1999 Sep; 126(3):568-76. PubMed ID: 10486611
[TBL] [Abstract][Full Text] [Related]
23. A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.
Hornberger J; Lyman GH; Chien R; Meropol NJ
Value Health; 2012 Dec; 15(8):1014-21. PubMed ID: 23244802
[TBL] [Abstract][Full Text] [Related]
24. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
25. Changing paradigms in breast cancer management: introducing molecular genetics into the treatment algorithm.
Rayhanabad JA; Difronzo LA; Haigh PI; Romero L
Am Surg; 2008 Oct; 74(10):887-90. PubMed ID: 18942607
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.
El Ouagari K; Karnon J; Delea T; Talbot W; Brandman J
Breast Cancer Res Treat; 2007 Jan; 101(1):37-49. PubMed ID: 16821085
[TBL] [Abstract][Full Text] [Related]
27. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
Asad J; Jacobson AF; Estabrook A; Smith SR; Boolbol SK; Feldman SM; Osborne MP; Boachie-Adjei K; Twardzik W; Tartter PI
Am J Surg; 2008 Oct; 196(4):527-9. PubMed ID: 18809056
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer.
Retèl VP; Joore MA; Knauer M; Linn SC; Hauptmann M; Harten WH
Eur J Cancer; 2010 May; 46(8):1382-91. PubMed ID: 20359886
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model.
Hillner BE; Smith TJ
N Engl J Med; 1991 Jan; 324(3):160-8. PubMed ID: 1898533
[TBL] [Abstract][Full Text] [Related]
30. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
31. The influence of a gene expression profile on breast cancer decisions.
Henry LR; Stojadinovic A; Swain SM; Prindiville S; Cordes R; Soballe PW
J Surg Oncol; 2009 May; 99(6):319-23. PubMed ID: 19204954
[TBL] [Abstract][Full Text] [Related]
32. Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapy.
Enewold L; Geiger AM; Zujewski J; Harlan LC
Breast Cancer Res Treat; 2015 May; 151(1):149-56. PubMed ID: 25859924
[TBL] [Abstract][Full Text] [Related]
33. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
Delea TE; El-Ouagari K; Karnon J; Sofrygin O
Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
[TBL] [Abstract][Full Text] [Related]
35. Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer.
Pusztai L; Broglio K; Andre F; Symmans WF; Hess KR; Hortobagyi GN
J Clin Oncol; 2008 Oct; 26(28):4679-83. PubMed ID: 18662965
[TBL] [Abstract][Full Text] [Related]
36. Use of a physician-directed questionnaire to define a consensus about management of breast cancer: implications for assessing costs and benefits of treatment.
Tannock IF; Belanger D
J Natl Cancer Inst Monogr; 1992; (11):137-42. PubMed ID: 1627419
[TBL] [Abstract][Full Text] [Related]
37. Expenditure audit of women with breast cancer in a tertiary care hospital of Delhi.
Pakseresht S; Ingle GK; Garg S; Singh MM
Indian J Cancer; 2011; 48(4):428-37. PubMed ID: 22293256
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
39. The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma.
Oestreicher N; Ramsey SD; McCune JS; Linden HM; Veenstra DL
Cancer; 2005 Nov; 104(10):2054-62. PubMed ID: 16216002
[TBL] [Abstract][Full Text] [Related]
40. A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer.
Davidson JA; Cromwell I; Ellard SL; Lohrisch C; Gelmon KA; Shenkier T; Villa D; Lim H; Sun S; Taylor S; Taylor M; Czerkawski B; Hayes M; Ionescu DN; Yoshizawa C; Chao C; Peacock S; Chia SK
Eur J Cancer; 2013 Jul; 49(11):2469-75. PubMed ID: 23611660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]